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ARTICLE
AI Applied to Cancer
A deep convolutional neural network for segmentation of
whole-slide pathology images identifies novel tumour cell-
perivascular niche interactions that are associated with poor
survival in glioblastoma
Amin Zadeh Shirazi 1,2, Mark D. McDonnell 2, Eric Fornaciari3, Narjes Sadat Bagherian4, Kaitlin G. Scheer 1, Michael S. Samuel 1,5,
Mahdi Yaghoobi6, Rebecca J. Ormsby 7, Santosh Poonnoose 7,8, Damon J. Tumes 1 and Guillermo A. Gomez 1
BACKGROUND: Glioblastoma is the most aggressive type of brain cancer with high-levels of intra- and inter-tumour heterogeneity
that contribute to its rapid growth and invasion within the brain. However, a spatial characterisation of gene signatures and the cell
types expressing these in different tumour locations is still lacking.
METHODS: We have used a deep convolutional neural network (DCNN) as a semantic segmentation model to segment seven
different tumour regions including leading edge (LE), infiltrating tumour (IT), cellular tumour (CT), cellular tumour microvascular
proliferation (CTmvp), cellular tumour pseudopalisading region around necrosis (CTpan), cellular tumour perinecrotic zones (CTpnz)
and cellular tumour necrosis (CTne) in digitised glioblastoma histopathological slides from The Cancer Genome Atlas (TCGA).
Correlation analysis between segmentation results from tumour images together with matched RNA expression data was
performed to identify genetic signatures that are specific to different tumour regions.
RESULTS: We found that spatially resolved gene signatures were strongly correlated with survival in patients with defined genetic
mutations. Further in silico cell ontology analysis along with single-cell RNA sequencing data from resected glioblastoma tissue
samples showed that these tumour regions had different gene signatures, whose expression was driven by different cell types in
the regional tumour microenvironment. Our results further pointed to a key role for interactions between microglia/pericytes/
monocytes and tumour cells that occur in the IT and CTmvp regions, which may contribute to poor patient survival.
CONCLUSIONS: This work identified key histopathological features that correlate with patient survival and detected spatially
associated genetic signatures that contribute to tumour-stroma interactions and which should be investigated as new targets in
glioblastoma. The source codes and datasets used are available in GitHub: https://github.com/amin20/GBM_WSSM.
British Journal of Cancer (2021) 125:337–350; https://doi.org/10.1038/s41416-021-01394-x
INTRODUCTION
Glioblastoma is the most frequently diagnosed and aggressive
type of brain cancer, accounting for 80% of primary malignant
brain tumours of the central nervous system (CNS), and 60% of all
malignant brain tumours in adults.1 There are ~100,000 new cases
of glioblastoma diagnosed each year worldwide,1,2 with a 1.6-fold
higher prevalence in men.3 While rare relative to overall cancer
incidence, glioblastoma accounts for 2.5% of total cancer-related
deaths.1
The clinical management of glioblastoma clinical management
has not improved in the last 30 years.4 First-line therapy for newly
diagnosed glioblastoma is maximal safe resection of the tumour,
followed by concurrent chemo-radiation and maintenance che-
motherapy.5 Despite these aggressive treatments, the disease
almost inevitably recurs, in which case there is no standard
treatment available.6 This lack of progress could be attributed to
two possible reasons (i) extensive intra- and inter-tumour
heterogeneity and (ii) the highly invasive and infiltrative nature
of these tumours, both of which are dependent on the interactions
of the tumour cells with the surrounding microenvironment.7
Gliomas are graded and categorised according to the World
Health Organization (WHO) guidelines based on a combination of
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histologic and molecular features.8 Grade IV gliomas correspond
to glioblastoma and essential diagnostic features include atypical
glial cells, brisk mitotic activity, evidence of microvascular
proliferation (MVP) and/or significant necrosis. MVP typically
appears as glomeruloid tufts of multi-layered endothelial cells
that are mitotically active along with smooth muscle cells or
pericytes. Necrosis is a fundamental feature of glioblastoma and,
together with the presence of blood vessels, is the strongest
predictor of aggressiveness.9–11
Although analysis of gene-expression data (bulk RNA-seq)
available from The Cancer Genome Atlas (TCGA) has enabled
the successful identification of the molecular signatures/biomar-
kers associated with the different GBM tumour subtypes, to date,
GBM treatment based on this information alone has not resulted
in improved patient survival.4,12 GBM treatment is further
complicated by the fact that glioblastoma tumours also exhibit a
high level of cancer cell heterogeneity and plasticity.13–19 Indeed,
tumour plasticity and the capacity of cancer stem cells to partially
and/or reversibly differentiate into different cancer cell popula-
tions is believed to be the main cause of resistance to therapy and
the development of tumour recurrence.13,16,20 Understanding the
mechanisms that contribute to glioblastoma plasticity and how it
is shaped by the tumour microenvironment (i.e. stem cell niches)
has been difficult. This is partly due to the lack of appropriate tools
to unravel the spatial and functional interactions that occur
between tumour cells and cells in the tumour niche, and to
predict which interactions are important regulators of cancer stem
cell plasticity and the capacity of cancer cells to infiltrate the
surrounding healthy brain tissue.12
Recently, a Decision Forests statistical machine learning-driven
algorithm (“Mill”) was used by the Ivy GAP to identify and segment
tumour regions and label the anatomic features in ~12,000
histological images, which were then laser-capture micro-dissected
and subjected to bulk RNA-seq.21 The Ivy GAP data constituted a
significant advance in the field and has allowed the identification of
signatures associated with different tumour regions.21 However, it
has limitations, as the results were highly dependent on the
segmentation algorithms that were implemented for the segmenta-
tion of the different tumour regions22–25 and inherently biased due
to the small number (n= 32) of patient samples analysed.21
Furthermore, although multiple sections/regions were processed
for data augmentation and the creation of the Ivy GAP database, the
small number of patients recruited to the project did not permit the
identification of genetic signatures or key demographic character-
istics associated with survival and/or particular molecular profiles of
the tumours.21 Moreover, the gain in insight into spatial resolution
by attributing gene signatures to specific tumour regions was not
translated into an understanding of the expression of these
signatures by specific cell types, as limited cellular ontology analysis
was performed on this data, due to the limited number of datasets
and bioinformatic tools at the moment of its publication. Conse-
quently, there is currently no available data that permits the
identification of the cell populations that are present in each of
these tumour anatomic locations and the corresponding transcrip-
tional programs that underpin tumour-stroma interactions that may
contribute to poor survival. Gaining insight into these aspects would
be critical to progress our understanding on the biology of these
very aggressive brain tumours.12
Here, we implemented a deep convolutional neural network
(DCNN) model for semantic segmentation of histopathological
(Haematoxylin-Eosin, H&E) images trained on the Ivy GAP dataset
to improve the quality of segmentation of different brain tumour
regions (Supplementary Fig. 1A). We sought a pathologist’s
opinion to advise on the removal of outliers (Supplementary
Fig. 1B includes some examples) in the input dataset and for
verification of results, that together contribute to improve the
accuracy of segmentation of different brain tumour regions. The
resulting model was then employed to segment TCGA
histopathological images and correlation analysis between gene
expression and tumour region size was used for the identification
of different gene signatures associated with different tumour
regions as well as the different cell types that express them. We
further combined these results with single-cell RNA sequencing
(scRNA-seq) data to investigate tumour-stroma interactions that
contribute to poor prognosis in glioblastoma.
METHODS
Histology image datasets
We used the Ivy GAP dataset, as the main dataset for training our
DCNN semantic segmentation model (GBM_WSSM). This dataset
includes 32 patients diagnosed by primary surgery type with a
total of 805 whole-slide images (WSIs) along with their corre-
sponding ground truths.21 Three distinct datasets (training,
validation and test) were created by randomly splitting the data
in the ratio of 14:1:1. Twenty eight patients with 687 WSIs were
allocated to the training dataset, two patients with 52 WSIs were
allocated to the validating dataset and two patients with 48 WSIs
were allocated to the testing dataset. The validation set was used
to evaluate the performance of our models during the training
phase while the test set includes unseen samples for checking the
model after training. An additional dataset was downloaded from
TCGA26 and includes 640 whole-slides H&E histopathological
images from 329 glioblastoma tumours. The GBM_WSSM was
applied to this dataset to produce the masks corresponding to all
patients. Those masks were then used for further biological
investigation as described in the paper.
TCGA RNA-Seq dataset
The following filters were applied to extract RNA glioma datasets
from TCGA for correlation analysis. Project: TCGA GBM, Disease Type:
gliomas, Vital Status: dead; Data Category, transcriptome profiling;
Data Type: RNA-Seq. The resulting cases were further filtered by the
availability of matched and successfully segmented whole-slide
images from the same tissue portion used for RNA-seq analysis
(Supplementary Table 1). FPKM-UQ data from this cohort of patients
was used and when available, replicates measurements from the
same patient were averaged. ENSG to gene name conversion was
performed using the Biomart tool from Ensembl (https://m.ensembl.
org/biomart/martview/e5476740b357b1b968ca8507fd4d853e) using
Homo sapiens (human) genome assembly GRCh38.p13 from
Genome Reference Consortium.
Image pre-processing
In the pre-processing stage, all WSIs and GTs from the Ivy GAP
dataset were first visually checked by the trained pathologist of
our team (N.S.B.) and 18 of 805 were removed as outliers
(Supplementary Fig. 1B) because of high-level noise presenting
poor segmentation in the masks. All images and masks were then
re-sized to four different scales: 4096 × 4096, 2048 × 2048, 1024 ×
1024 and 512 × 512 from the original size 18,000 × 15,000.
Afterwards, different sizes of patches (1024 × 1024, 512 × 512,
256 × 256) were systematically extracted (not randomly) from the
re-sized images and their masks. Therefore, the extracted patches
were the entire datasets obtained from images and used in the
training phase. Patches were then normalised by using a pixel-
normalisation method into the domain [0,1] by dividing all pixel
values by the largest pixel value among all patches i.e. 255. For
data augmentation purposes, random crops and vertical flips were
applied in the training phase to all models.
Algorithms
For semantic segmentation of the eight different brain tumour
regions inside the GBM WSIs, a customised fully convolutional
DenseNets for semantic segmentation with 103 layers (based on
the tiramisu design)23 was trained and validated on the normalised
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patches. These regions include (Fig. 1a) leading edge (LE), infiltrating
tumour (IT), cellular tumour (CT), cellular tumour microvascular
proliferation (CTmvp), cellular tumour pseudopalisading region
around necrosis (CTpan), cellular tumour perinecrotic zones (CTpnz),
cellular tumour necrosis (CTne) and background (BG, i.e. area void of
tissue). Spearman correlation analysis (Matlab 2019b, see also
Supplementary Materials 1, 2 and 3) between gene expression
and brain tumour region size was used to identify genetic signatures
that are specific to each tumour region (Supplementary Table 2). p-
values against the null hypothesis that there is no correlation
between these variables were calculated for each Spearman
correlation test and are also included in Supplementary Table 2.
These p-values were not corrected for multiple comparisons27–30
since (i) the p-value distribution is not the same across all brain
tumour regions and is not always uniformly distributed (Supple-
mentary Fig. 2, A and B), and (ii) there are significant correlations
within each of the variables (i.e. genes vs genes expression; region
size vs region size) used for Spearman calculations (Supplementary
Fig. 2, C), which suggest that multiple Spearman tests were not fully
independent of each other.
Performance evaluation
We trained 49 different networks and used the random search
approach for hyperparameter tuning in each one (Supplementary
Table 3). We used sparse categorical cross-entropy, and RMSprop,
as loss function and optimiser method, respectively. The number
of epochs in different experiments varied between 30 and 150. For
prevention of overfitting, dropout technique and L2 weight
regulariser were applied. Experiments’ performance comparison
was performed based on the evaluator used in the original
paper23 and by using pixel-wise classification accuracy, where
each predicted pixel in the mask produced by a DCNN model is
compared with the corresponding pixel in the original
ground truth.
Hardware and software
We used python as the programming language, Keras,31 a high-
level neural networks API with the Tensorflow platform,32 and
trained all networks using four NVIDIA 1080Ti GPUs. PRISM and
Matlab2019b were used for Pearson’s and Spearman correlation
analysis (codes provided Supplementary Materials 1, 2 and 3).
Survival plots were generated in Matlab using MatSurv function,33
Cell ontology analysis was performed using CellKb (https://www.
CellKb.com.34), Clustergrams were generated using Morpheus
(https://software.broadinstitute.org/morpheus) and Matlab2018
(Supplementary Materials 1). Euclidean distance was used for
clustering of variables. Venn diagrams were drawn using












GBM_WSSM application in testing phase
(IVY-GAP dataset)
Optimised hyper-paramaters for semantic segmentation
(experiment # 47, Supplementary Table 1)
Original image Ground truth Predicted mask
b
ca
LE IT CT CTpnz CTpan CTmvp BGCTne
Brain Tumour regions colorcode
Value|type
Resized WSIs (pixels) 1024 × 1024
Patch size (pixels) 512 × 512
Total number of training patches 2748
Total number of validating patches 208
Total number of classes (incl. background) 8
Image augmentation technique Random crops & vertical flip
Hyper-paramaters tuning technique Random search
Model inputs 224 × 224
Batch size 16
Optimiser method RMSprop
Epochs & patience 55 & 50
Learning rate 1 × 10–3
Learning rate recay 5 × 10–5
Loss function Sparse categorical crossentropy
Weight regulariser L2
Weight decay 1 × 10–4
Dropout 0.2
Fig. 1 The training and testing phases of the GBM_WSSM model on the IVY-GAP dataset. a Schematic representation of different brain
tumour regions in glioblastoma. b Optimal experiment details for GBM WSI semantic segmentation model (GBM_WSSM). c Representative
images from segmentation results of the proposed model in the testing phase (GBM_WSSM segmentation superiority has been shown by
black arrows).
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Gorilla36 and network graphs generated using Cytoscape.37
Scientific Illustrations were created with BioRender.com and all
Figures were compiled using Adobe Illustrator 2020.
scRNA-seq experiments and data analysis
Preparation of samples, library preparation and bioinformatic
pipelines for the generation of curated scRNA-seq data from three
resected glioblastoma tissue samples was described before.38 Cell
quality control and clustering were done using Seurat version
3.039 as we described before38 and analysis of paracrine
ligand–receptor pairs between clusters were done using
SingleCellSignalR.40
We use average expression per cluster of differential expressed
genes in this data for analysis of cell ontology and hierarchical
clustering analysis.
RESULTS
A DCNN model improves semantic segmentation accuracy of
whole-slides histopathological images of glioblastoma
Large labelled datasets are essential parts of the training phase of
the deep learning models with supervised learning. Sometimes, it
can be seen that the labels (ground truths) for training deep
learning models have been generated by non-experts or
automated methods and hence, the level of noise in such labels
is typically higher than the labels annotated by experts. However,
recent studies confirm that DCNNs are extremely robust to handle
the high level of noisy labels in supervised learning approaches
since well-designed DCNNs applied to sufficiently large and
diverse dataset do not memorise the data and they learn the
dominant patterns shared among all samples.41
The Ivy GAP portal (http://glioblastoma.alleninstitute.org/) is a
freely accessible online database that contains GBM slides and
their corresponding ground truths annotated using a statistical
machine learning method. Although this dataset is very helpful for
further research, we identified variable segmentation accuracy in
some masks by manual inspection.
Because of the wide use of the Ivy GAP histopathological
images database within the brain cancer research community, we
decided to use the GBM slides and their corresponding labels from
the Ivy GAP to train a deep convolutional neural network (DCNN)
architecture and obtain a semantic segmentation model of
glioblastoma histopathological images. To increase the accuracy
of the semantic segmentation model, we took the advantage of
DCNN models in addressing noisy labels41 and introduced the
pathologist opinion after the training phase of each experiment
(Supplementary Fig. 1, Supplementary Table 3). Then, the best
model was applied to TCGA as a larger database containing more
GBM patients to segment its GBM slides.
Our results indicated that WSI and mask re-sizing from its
original size 18,000 × 15,000 to 1024 × 1024 and extracted patches
with the size of 512 × 512 led to the highest segmentation
accuracy, reaching ~70% determined by pixel by pixel comparison
(model 47 in Supplementary Table 3, and Fig. 1b). However, when
compared to the original H&E image, the model accuracy was
better than the ground truth (as can be seen in Fig. 1c). In this
figure, it can be seen that the segmentation accuracy in our model
is better than that achieved in the original GTs, particularly in the
third and fourth examples shown by the black arrows and the red
polygons. Based on our pathologist’s advice, our implemented
DCNN model in segmentation of GBM slides has the following
advantages (in comparison with the original GTs produced by a
statistical machine learning model):
● The DCNN model can segment unclear regions in the original
slide (Fig. 1c, iii)
● The DCNN model is able to properly detect the regions
corresponding to the Infiltrating Tumour (specified by the
purple colour) and Cellular Tumour Necrosis (specified by the
black colour) regions without over-segmenting the Leading-
Edge region (Fig. 1c, iv)
● The DCNN model can tackle the problem of over-
segmentation of the Cellular Tumour Microvascular Prolifera-
tion region (specified by the orange colour in the masks,
Fig. 1c, i, ii, and iv)
● The DCNN model can tackle the problem of over-
segmentation of the Cellular Tumour (specified by the green
colour) region (in almost the majority of the masks produced).
We reported the results using the global accuracy metric across
all eight classes23:
Accuracy ¼ TPþ TN
TPþ TNþ FPþ FN
This equation calculates the ratio of the correctly classified
pixels (TP+ TN) with regard to the total pixels (TP+ TN+ FP+
FN). We have used the accuracy metric as an evaluator to compare
between our 49 different DCNN experiments during the training
phase, hyper-parameters tuning, and to select the best models.
For this purpose, we applied the Human_In_The_Loop (HITL)
approach, which is a setting in a loop where an expert can insert
prior knowledge into an AI machine to enhance its output.42 In our
case, the HITL approach entailed our pathologist supervising/
evaluating the results (segmented masks) obtained by the
experiments with the better performance (i.e. higher accuracy,
see also Supplementary Fig. 1). Subsequently, if the results were
not satisfactory (based on the pathologist’s opinion), even if the
accuracy values achieved by the experiment was good, the
experiments were repeated by adjusting the hyper-parameters to
eventually achieve a better segmentation result among all regions
than the previous model producing the original GTs. Furthermore,
while we have eight distinct regions/classes, we do not see a
significant class imbalance in the original GTs, particularly in the
main parts i.e. Cellular Tumour, Infiltrating Tumour, Leading Edge
and Necrosis. The Background (BG) region also covers a small
portion of each GT and the ~70% segmentation accuracy has
been achieved among all eight classes. For simplicity, we call our
best model “GBM_WSSM”.
Different brain tumour regions are associated with distinct GBM
mutation profiles that are indicative for poor prognosis
We then applied the GBM_WSSM to the GBM TCGA dataset of
whole-slide H&E stained histopathological images. This dataset
includes 640 whole-slide images from 329 glioblastomas. All the
WSIs were re-sized and fed to the GBM_WSSM as new inputs and
their corresponding masks were produced (Fig. 2a), which were
also evaluated by our team pathologist for segmentation
accuracy. To produce a numerical dataset, the area of the masks
for different tumour regions were quantified across all 329 samples
analysed. For tumour region quantification, we used the averaged
pixel counting approach. In this approach, for each patient, the
same pixels related to one region are counted across all masks of
that patient and then, the counted value is averaged over the
number of slices. This was performed in order to capture the total
amount of tumour region across different sections and have a
better representation of the volume (measured as total number of
pixels) that each of these occupies in the portion of tissue
analysed at the same time that normalises the total number of
pixels detected for each region by the number of sections
available for each patient, as, in many instances, for each patient,
there are the different number of available sections. Figure 2b
shows the quantified regions for some of the patients. The Grubbs’
test43 was then applied on this numerical dataset and 27 outliers
were removed in order to obtain a normally distributed survival
data, which is required for the analysis of the relationship between
A deep convolutional neural network for segmentation of whole-slide. . .
A Zadeh Shirazi et al.
340
i. Haematoxylin and eosin whole slide images of glioblastoma tissue 
ii. GBM_WSSM segmentation results
GBM_WSSM application on TCGA dataset
LE IT CT CTpnz CTpan CTmvp BGCTne
Brain tumour regions colorcode
Patient ID LE IT CT Ctne CTpnz Ctpan CTmvp Survival
TCGA-12-0657 0.07947236 0.00599 0.28339 0.3113 0.24804 0.00632 0.00107 0
TCGA-19-2624 4.05E-05 0 2.54E-05 0.2573 0.00407 0 0 0.001692
TCGA-41-4097 5.06E-06 0 0.02373 0.0407 0.06112 0.02039 0.10282 0.0025381
TCGA-06-0201 0.000399804 0.00026 0.06448 0.3658 0.13025 0.00042 0.00033 0.0076142
TCGA-06-0213 0.00069333 0.00246 0.5345 0.3242 0.09362 0.03586 0.06649 0.0109983
TCGA-19-0962 0 0 2.18E-05 0.4407 0.00457 0 0 0.0143824
TCGA-02-0439 5.06E-05 1.84E-05 0.85548 0.0204 0.14608 0.02927 0.00919 0.0143824
TCGA-06-0219 0.028461971 0.15673 0.09035 0.52 0.01766 0.00947 0.0148 0.0160745
TCGA-08-0392 0.000652844 0 0.02348 0.4412 0.08101 0.0003 2.53E-05 0.0160745
TCGA-41-2571 1.27E-05 0 0.00611 0.0312 0.02253 0.00334 0.0038 0.0194585
TCGA-14-1455 0.001665005 0.00345 0.02905 0.0242 0.03333 0.02147 0.00775 0.0211506
TCGA-06-0750 0.211536612 0.03137 0.03957 0.3258 0.0175 0.01608 0.15943 0.0211506
.










































































































































Fig. 2 The application of the GBM_WSSM model to the TCGA dataset. a Representative results from GBM_WSSM application on the TCGA
samples. (i) WSIs from TCGA. (ii) Corresponding masks produced by GBM_WSSM. bMeasurement of different tumour regions (normalised) and
patient survival in each TCGA glioblastoma case. c Dot plot graph of the results shown in b. d Pearson correlation values between survival
rates and normalised areas corresponding to each tumour region (asterisk denotes p < 0.05). Comparable statistically significant results were
obtained in the presence or absence of outliers using Spearman correlation analysis, which is less sensitive to the presence of outliers.
e Distribution of glioblastoma patients harbouring specific oncogenic mutations in TCGA. f Heatmap plot of Pearson correlation values
between the size of the tumour regions and survival rates.
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segmentation results and patient survival through the calculation
of correlation coefficients44,45 (Supplementary Table 4).
The results of tumour region size quantification revealed that
across the set of TCGA glioblastoma tumours, large areas of WSI
images contained brain tumour regions corresponding to the
cellular tumour mass including the CT, CTne and CTpnz regions
(Fig. 2c, Supplementary Fig. 3, Supplementary Table 4).
This is expected as these regions are the primary focus of the
neurosurgery and are thus more likely to appear in resected
samples. Other more peripheral regions exhibit higher variability,
likely due to differences in surgical procedures and the ability to
delimit the tumour boundaries during the operation. With this in
mind, we believe our segmentation results agreed with what
would be expected from the analysis of data derived from samples
collected in multiple centre/institutions, where practices and
experimental protocols might not be standardised across the sites
and site-to-site differences are likely to be present.
We have previously shown that DCNN models can be trained
and applied to TCGA H&E histopathological images to predict
brain cancer patient survival46 (see also review in ref. 47). To
analyse the relationship between segmentation results and
patient survival, we next performed Pearson correlation analysis
between the area of different brain tumour regions and patient
survival across (i) all TCGA glioblastomas, and (ii) brain tumours
harbouring the 13 most frequent mutations (PTEN, TP53, EGFR,
NF1, PIK3CA, PI3KR1, TRAPP, ATRX, PDGFRA, KMT2C, PB1, GRIN2A,
IDH1; see Supplementary Fig. 3 for tumour region size distribution
across different patient’s cohorts). When we analysed all patients
in the TCGA GBM cohort, we found that survival rates are
positively correlated with the area CT and CTpnz but poorly
correlated with other regions (Fig. 2d). The relatively low
correlation values could be due to the heterogeneous nature of
the data (i.e. pooled across all patients). To determine if this was
the case, we next stratified our analysis by patients harbouring
specific oncogenic mutations (Fig. 2e). Mutation-specific stratifica-
tion resulted in higher correlation values between tumour region
size and survival rates and also revealed new additional cases
where region size was negatively correlated with survival (Fig. 2f).
In brain tumours harbouring mutations in the PIK3R1 and PB1
genes, the presence of LE, IT and CTmvp regions negatively
correlated with patient survival, likely reflecting the highly
infiltrative nature of tumours bearing these histologies.48–50
Moreover, in patients harbouring mutations in the PDGFRA,
KMT2C or EGFR genes, we observed a negative correlation
between the presence of highly vascularised tumour regions
and patient survival, again reflecting the more aggressive
phenotype of this type of tumour. Interestingly, we also note that
in patients harbouring mutations in the NF1, PTEN, TRAPP, TP53
and PIK3CA, there is a strong positive correlation between survival
and central tumour regions (i.e. CT and CTpnz) but little or no
correlation with the other infiltrative regions LE, IT and CTmvp).
This probably reflects non-invasive and therefore more benign
tumours. Overall, these results highlight the varying influence of
gene mutations on histopathological features and reveal tumour
features associated with prognosis. These data also highlight
critical differences that significantly influence the biology of these
tumours and their capacity to escape complete resection during
surgery as well as to develop therapy resistance.
Gene signatures of specific brain tumour regions are associated
with distinct biological processes in tumour biology and are
indicative of patient survival
RNA-seq data from GBM patients in TCGA enabled us to identify
gene signatures (markers) associated with each of the different
regions. We reason was that genes specific to one region would
show higher expression in tumour samples where the area for that
region (measured as the total pixel count) is bigger. For this, we
used Spearman correlation analysis results between gene
expression (>35,000 genes, whose expression was detected in at
least 25 patients) and brain tumour area for different brain tumour
regions. The results indicated that for different regions, there are
both positively and negatively correlated genes (Fig. 3a, Supple-
mentary Table 2). Of these, we focused only on positively (ρ > 0.1)
and significantly (p < 0.05) correlated genes (Fig. 3b, Supplemen-
tary Table 2). Overall, we found that the different brain regions
have different numbers of genes that behave as “markers”
according to our definitions, with IT and CTmvp regions exhibiting
the largest number of marker genes (174 and 373 genes,
respectively, Fig. 3c, Supplementary Table 5). Importantly, our
analysis validated many of the genes previously annotated as
markers in the Ivy GAP Database (Fig. 3d). However, the number of
genes identified in the Ivy GAP project was considerably larger
than the number that we identified. This is likely due to the fact
that not all markers identified in Ivy GAP have a prognostic value
as well as the lowest accuracy of Ivy GAP segmentation results,
which coupled to analysis of the fewer number of patients, could
also lead to a significant increase in the number of false positives.
Next, we analysed the relationship of the region-specific gene
signatures with patient survival, which was possible due to the
large number of patients whose data are available in the TCGA
glioma database (n= 129). We found that most of the genes in the
CT and CTpnz signatures positively correlated with survival, which
agreed with our previous observation in cohorts of patients with a
specific set of mutations (Fig. 2d, 3c). We also found that for LE,
CTne and CTpan, an approximately equal number of genes
positively and negatively correlated with patient survival (Fig. 3c).
Interestingly, we found that in IT and CTmvp, the regions with
more specific markers, most genes negatively correlated with
survival (Fig. 3c). This is consistent with tumour infiltration into the
surrounding brain tissue being unfavourable for complete surgical
resection and with the capacity for infiltrating tumours to rapidly
develop therapy resistance, which together contributes to poor
patient survival.
These results revealed different gene signatures for different
regions that have different correlations with patient survival. In
order to gain insight on these, we then focus on IT and CTmvp
gene markers whose expression is negatively correlated with
patient survival (ITneg and CTmvpneg) as well as CT and CTpnz
gene markers whose expression is positively correlated with
patient survival (CTpos and CTpnzpos). Gene ontology (GO)
biological processes analysis allowed us to investigate the cellular
processes associated with these gene signatures (Fig. 3e, f and
Supplementary Fig. 4, Supplementary Table 6). For the ITneg
signature, we identified several GO processes, including cell
proliferation in midbrain and regeneration, possibly reflecting the
stem-cell-like properties of tumour cells in those regions.16,19,51
Processes involving ‘glial cell migration’, ‘locomotion’, ‘cell
contractility’, ‘cell movement’ and ‘lymphocyte migration’ were
also identified to be associated with the gene signatures specific
to this region. This highlights the migratory and invasive potential
of cancer cells52 as well as the motility of microglia and
lymphocytes, suggesting that in the IT region these different cell
types within the microenvironment may be cooperating to
enhance the invasive capacity of glioblastoma cells.53 Interest-
ingly, several GO processes that belong to stress cell responses
were also identified in this region (i.e. response to: ‘cycloheximide’;
‘organic’ and ‘inorganic’ substances; ‘glucocorticoids’, and to
‘chemicals’), again reflecting properties of the microenvironment
to which tumour and inflammatory cells are exposed.16
GO biological processes analysis revealed a more complex
microenvironment in the CTmvpneg signature relative to ITneg.
Important GO processes associated with this signature corre-
sponded to ‘immune’ and ‘immune-inflammatory responses’,
‘cytokine signalling’ and ‘regulation of leukocyte proliferation’,
indicating a fine regulation of immune responses in the tumour
microenvironment in CTmvp regions. Other key GO processes
A deep convolutional neural network for segmentation of whole-slide. . .
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Fig. 3 Gene expression analysis in the TCGA segmented tumour regions. a Hierarchical cluster analysis (columns only) of Spearman
correlation coefficients (ρ) between gene expression and tumour region area measurements for the cohort of TCGA patients in
Supplementary Table 1. This cohort was obtained from TCGA cases that have both RNA-seq and WSI data available (See Supplementary
Table 4 for Spearman and p-values numerical results). b Columns for IT, LE, CTne, CT, CTpna, CTpnz and CTmvp are same as in A but the data
was filtered for genes that have ρ > 0.1 and this correlation is significantly different from the null hypothesis of no correlation (p < 0.05). The
‘survival’ column shows Spearman correlation coefficient values between patient survival and gene expression for all the genes analysed. c Bar
graph showing the number of markers for each tumour region whose expression is positively and negatively correlated with patient survival
(See Supplementary Table 5 for the list of genes for each condition). d Venn diagram showing the comparison of gene markers for each
tumour region identified in this work and previously by Puchalski et al.21 e, f Summary of GO: Biological Processes analysis for ITneg and
CTmvpneg gene signatures (see also Supplementary Table 6 for process description, p-values and genes associated to each process). The
network was simplified by highlighting only GO: Biological Processes with log (p-value) <−3.5 and the nodes (i.e. GO: Biological Processes)
colour coded (red levels) to highlight the more significant processes associated to each signature. Colour bar indicates different p-values for
each node.
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identified in this region included ‘secretion by cell’, ‘vesicle-
mediated transport’, ‘collagen metabolism’, ‘cell motility’, ‘locomo-
tion, ‘extracellular matrix (ECM) organisation’. These are related to
the regulation of ECM production and the interaction of that ECM
with cells and is consistent with the capacity of tumour cells to
interact with the ECM surrounding the vasculature and infiltrate
healthy brain tissue along the microvasculature.54
In contrast to the ITneg and CTmvpneg signatures, the CTpos and
CTpnzpos gene signatures showed a strong connection to those
processes related to DNA, RNA and protein synthesis through
different metabolic pathways, that align overall with higher
macromolecule synthesis rates required by highly proliferative
tumour cells (Supplementary Fig. 4). Taken together, these results
establish the power of using AI to segment tumour regions in
many patient-derived samples and the use of this information for
the identification of gene signatures characteristic of each region.
Gene signatures in different brain regions predict the presence of
specific cell types in the tumour microenvironment
The diverse GO processes associated with the different gene
signatures motivated us to investigate the identity of the cells that
express these signatures in the different tumour regions.
Accordingly, we investigated the cell types that are more likely
to express these gene signatures in each tumour region using
CellKb application software, which uses publicly available scRNA-
seq data to predict the cells types that are likely to express a list of
differentially expressed genes (“match score”34). This match score
is calculated for each cell type and correspond to the sum of rank-
based scores calculated for overlapping genes between the query
and the cell type. The match score thus accounts for the gene
rank, the difference in gene ranks and the total number of
significant genes in the cell type. Using CellKb, we obtained a list
of cell types and for each cell type an associated match score and
a list of genes specific for that cell type (Supplementary Table 7).
In this list, a cell type may be predicted more than once, since
multiple databases (scRNA-seq experiments) were used. Thus, to
uniquely assign a cell type to our gene signature, we weighted the
analysis for not only using the cell type match score but also
taking into account the number of times a particular cell type was
predicted using this analysis (Fig. 4ai–iv, Supplementary Table 8).
The results revealed that IT markers that are negatively correlated
with survival (ITneg) are predicted to be highly expressed by
microglial cells (CL:0000129) and monocytes (CL:0000576). This is
consistent with the GO processes discussed above but highlighted
a key non-cell autonomous role of the tumour microenvironment
(microglia) in the poor prognosis of glioblastoma. Cells in
CTmvpneg compartment also exhibited monocyte/microglia char-
acteristics. Moreover, this compartment also included cells
expressing genes that are specific for macrophages
(CL:0000235), endothelial cells (CL:0000115), dendritic cells
(CL:0001056), cerebral cortex endothelial cells (CCEC,
CL:0001056). Fibroblasts are probably representative of pericytes,
which coat blood vessels and contribute to the architecture and
function of the blood–brain barrier. The results thus indicate that
the genes characteristic of these different regions, that are
associated with poor patient prognosis, are more likely expressed
by cells of the tumour microenvironment than the cancer cells.
Finally, we performed cell ontology analysis on the CTpos and
CTpnzpos regions. These regions are expected to be enriched in
tumour cells, which was supported by our analysis revealing that
neoplastic cells are more likely to express the gene signature
corresponding to each region. Interestingly, T cells were only
associated with the CTpnz, a potential inflammatory region that
might chemoattract T cells (Fig. 4a). These data also indicate that
this region may be particularly important for targeting with
checkpoint inhibitor therapy.55
CellKb analysis also incorporates scRNA-seq data from a large
database of scRNA-seq studies from a range of tissues and disease
states that do not necessarily correspond to glioblastoma tumour
tissue. We therefore sought to validate our results using scRNA-
seq data that we obtained from three glioblastoma patients.38 Our
previous analysis using cell markers for different cell types in the
literature allowed us to define the different cell populations in the
scRNA-seq UMAP plots. The tumours analysed were principally
composed of glioma-associated macrophages (including microglia
and macrophages), lymphocytes, endothelial cells, pericytes and
tumour cells.38 In order to map the gene signatures identified by
semantic segmentation to this data, we first re-analysed our
scRNA-seq data using CellKb (Supplementary Table 9). Using this
approach, we were able to assign a cell ontology type to each of
the different cell clusters in the data derived from each individual
patient (Fig. 4b, Supplementary Table 10), which correlated well
with our previous manual cell assignment.38 Once individual
clusters were analysed, we then calculated the average expression
of each gene in the gene signatures of the CTpos, ITneg and
CTmvpneg regions and performed hierarchical clustering to
determine which cell types within the brain tumour expresses
each of the genes in the different gene signatures that we
identified for each region (Fig. 4c, Supplementary Figs. 5 and 6,
Supplementary Tables 11–13).
Consistent with our results examining gene expression in
publicly available scRNA-seq datasets, we found that the gene
signature associated with CT tumour regions is predominantly
associated with neoplastic tumour cells across the three patient-
derived samples analysed (Supplementary Figs. 5 and 6).
Furthermore, a group of genes within this signature was identified
to be specifically associated with T, B and NK cells. However, no
significant expression of these genes was observed in the
microglia/macrophages lineage, which contrasted with what we
observed in the corresponding results of the IT and CTmvp
regions (Fig. 4c). In these regions, a considerable number of genes
of each signature were expressed by cell types including
macrophages, microglia and monocytes. A larger number of
genes within CTmvp gene signature were also expressed in these
cell types compared to that in the IT gene signature. We also
observed that pericytes and endothelial cells express a significant
number of genes that match the CTmvp signature and a smaller
number of genes in the IT signature. Overall, these results
reinforce the notion that different brain tumour exhibit different
microenvironment properties and cellular compositions that may
contribute to prognosis in glioblastoma.
Gene signatures in different brain regions may mediate tumour-
microenvironment interactions
Our cell ontology results indicate that different cell types in the
tumour microenvironment contribute to poor patient prognosis.
However, the molecular events underpinning this effect are
unknown. A possibility is that the gene signatures mediate specific
types of cell–cell interactions between tumour cells and the
surrounding microenvironment (Fig. 5a). To investigate this, we
performed a bioinformatic analysis to explore paracrine
ligand–receptor interactions between the previously defined cell
clusters in our scRNA-seq data by focusing on ligand–receptor
pairs where the tumour cells express the receptor (Fig. 5a). For
this, we used the recently developed approach to identify
paracrine interactions since it includes one of the most
comprehensive datasets for this type of analysis.40 After running
this bioinformatic pipeline and filtering the results for (i) receptors
identified in the IT or CTmvp gene signatures, and;—(ii) expression
of the ligand–receptor pair in all three patient-derived scRNA-seq
datasets; we identified the reticulon 4 (RTN4): Gap junction beta-2
protein (GJB2) paracrine ligand–receptor pair as a potential
mediator of cell–cell interactions between tumour cells and the
surrounding microenvironment56 (Fig. 5b, Supplementary
Table 14). The RTN4 gene (also known as NOGO) encodes three
isoforms (isoforms A-C) with Nogo-A enriched in the central
A deep convolutional neural network for segmentation of whole-slide. . .




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0. Microglial cell (CL:0000129)
1. Endothelial cell (CL:0000115)
2. Pericyte cell (CL:0000669)
3. Neoplastic cell (CL:0001063)
4. Neoplastic cell (CL:0001063)
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6. Macrophage (CL:0000235)
7. T cell (CL:0000084)
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13. Endothelial cell (CL:0000115)
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2. Macrophage (CL:0000235)
3. Neoplastic cell (CL:0001063)
4. T cell (CL:0000084)
5. Microglial cell (CL:0000129)
6. Natural killer cell (CL:0000623)
7. Pericyte cell (CL:0000669)
8. Monocyte (CL:0000576)
9. Endothelial cell (CL:0000115)
0. Macrophage (CL:0000235)
1. Microglial cell (CL:0000129)
10. Neoplastic cell (CL:0001063)
11. B cell (CL:0000236)
12. Macrophage (CL:0000235)
2. T cell (CL:0000084)
3. Macrophage (CL:0000235)
4. Neoplastic cell (CL:0001063)
5. Endothelial cell (CL:0000115)
6. Dendritic cell, human (CL:0001056)
7. CD8+, – T cell (CL:0000625)
8. Pericyte cell (CL:0000669)
9. Neoplastic cell (CL:0001063)
10. Microglial cell (CL:0000129)
11. Pericyte cell (CL:0000669)
12. GABAergic neuron (CL:0000617)
13. Macrophage (CL:0000235)
14. Smooth muscle cell (CL:0000192)
15. Glutamatergic neuron (CL:0000679)
16. Endothelial cell (CL:0000115)
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Fig. 4 Cell ontology analysis in GBM tumour regions. a (i–iv) Cell ontology analysis for the ITneg, CTpos, CTpnzpos and CTmvpneg gene
signatures. The dotted line corresponds to the standard deviation calculated from the average match score across all cell types. b Cell type
assignment to each of cell clusters from scRNA-seq data derived from three glioblastoma resected tissue samples. c Cluster analysis of average
gene expression for genes in the ITneg and CTmvpneg signatures in different cell types identified in our scRNA-seq data (See Supplementary
Fig. 6 for a high-resolution image that also includes the corresponding gene names).
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nervous system (CNS). NOGO isoforms contain two transmem-
brane domains and are localised through the exocytic pathway,
plasma membrane and cell–cell junctions where it also interacts
with cadherin 5 (Cdh557). NOGO proteins have been implicated in
glioma cell invasion,58 tumour angiogenesis59 and regulation of
blood vessel homeostasis.60,61 In contrast, gap junction protein 2B
(GJB2, also known as Connexin26) is a structural component of
gap junctions62–67 and is expressed at the plasma membranes of
cells. GJB2 has previously been identified as a gene associated
with prognostic value in brain68,69 and pancreatic cancers70,71 and
contribute to tumorigenesis in breast cancer.72 Survival plots of
TCGA GBM data for patients with low and high expression of GJB2
and RTN4 reveal their association with a poor prognosis in
glioblastoma (Fig. 5c).
DISCUSSION
Here, we used DCNN for semantic segmentation of different brain
tumour regions on TCGA GBM datasets that contain matched
histopathological images, patient demographics and gene-
expression data. DCNN is a robust tool that can handle the
high-level noise in ground truths41 derived from semantic
segmentation results using machine learning models, that has
low-level accuracy.23
Using results acquired using DCNN, we have identified specific
markers for each of these tumour regions and evaluated their
prognostic value in glioblastoma. Moreover, we combined this
information with scRNA-seq experiments to determine the cohort
of different cell types within these regions that express the genes
associated with these signatures as well as protein–protein
interactions that mediate tumour-stroma relationships that can
serve as potential targets for glioblastoma.
Several studies have been undertaken to characterise gene
signatures relating to the tumour microenvironment.21,73–75
However, it has not been possible until now to investigate the
spatial organisation and possible roles of non-cancer cell types
that populate the microenvironment76 and pinpoint their
occurrence within the context of different brain tumour regions.
Amongst, the most notable is the pioneering work by the Allen
Institute that lead to the generation of the Ivy GAP database. By
using laser microdissection and bulk RNA sequencing, this effort
has generated spatial information about the different tumour
regions within glioblastomas and associated genetic signatures
with them. However, a limitation of this database, is that gene-
signature results were derived from laser microdissection of a
relatively small number of independent glioblastoma tissue
samples (n= 32). Although our gene signatures exhibited some
overlap with the gene signatures in the reported in the Ivy GAP
database, our gene signatures had fewer genes. This is probably a
consequence of the thresholds we applied for the correlation
coefficient and the p-value, to define the different gene signatures
and the fact that Ivy GAP tumour regions markers were defined by
differences in expression between regions, which is distinct from
the correlation versus no correlation approach between gene
expression and brain tumour regions taken in this study.
Interestingly, our analysis permitted the identification of a large
number of genes that did not overlap with the results from Ivy
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Fig. 5 GBM tumour-microenvironment interactions and survival analysis. a Schematic representation of different tumour-stroma
interactions in glioblastoma. b Summary of potential ligand–receptor interactions identified in our dataset. Please note that GNAS (a Gα
subunit) and PTGIR (a G protein-coupled receptor) interacts on the cytoplasmic side of the plasma membrane. Supplementary Table 14
provides a full list of ligand–receptor pairs identified in this work. c Survival plots of TCGA GBM data for patients with low and high expression
of GJB2 and RTN4 reveal their association with a poor prognosis in glioblastoma.
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AI for segmentation and the possibility of analysing large datasets
to be able to perform robust correlation analysis for the
identification of gene signatures.
The results of multiple laboratories performing scRNA-seq
experiments using cellular suspensions derived from resected
tumour tissue13–17,19,20,38,77 as well as bioinformatics approaches
designed to extract microenvironment features from bulk RNA-seq
data in TCGA78 have significantly advanced the characterisation of
the genetic signatures and cellular composition of the tumour
microenvironment in glioblastoma. These previous studies have
provided significant insight into the tumour cell heterogeneity in
glioblastoma as well as the cellular composition of the tumour
microenvironment.79 Moreover, these experiments have not only
provided a better understanding of tumour plasticity but also the
transcriptional program changes that occur in different cell types
in the tumour microenvironment.77 However, it has not been
possible until now to investigate the spatial organisation of non-
cancer cell types that populate the microenvironment and
pinpoint their occurrence within the context of different brain
tumour regions. In a recent study, Rajapakse et al. used
computational modelling to define cancer cell states and allocate
active and dormant cancer cell types within these different
tumour regions.80 In contrast, in this work, we combined publicly
available scRNA-seq data (using the CellKb platform) and our own
experiments to determine the gene signatures expressed by
different cell types in the microenvironment and how these relate
to different tumour compartments. Although spatial transcrip-
tomics81–83 and multiplex immunofluorescence imaging74,75
approaches can offer similar outcomes to that presented here,
these techniques are still prohibitively expensive and time-
consuming. We expect these results to facilitate the spatial
analysis of tumour biopsies and promote the adoption of
complementary techniques such as spatial transcriptomics81–83
and highly multiplexed immunofluorescence imaging.74,75
Although expensive and time-consuming, these approaches
enable high-resolution detection of RNA or protein in tissue
sections, which facilitates precise spatial analysis of the tumour
microenvironment and measurements of distances (and possible
interactions) between different cells of interest when combined
with single-cell RNA sequencing analysis.84
scRNA-seq data have also proved to be a powerful tool for
assessing potential protein–protein interactions that can control
tumour cell behaviour.40,85 Using these methods, we investigated
membrane receptors expressed on tumour cells that can interact
with secreted and/or membrane proteins, and determined
whether these ligand–receptor interactions are part of the gene
signatures that we have identified. Interestingly, we found the
GJB2 (also known as connexin 26): RTN4 (also known as NOGO)
pair in the CTmvp signature, with both genes being indicative of
poor prognosis in glioblastoma.
Although the role of connexins has been primarily associated
with its ability to function as hemichannels forming a direct
transmembrane communication pathway between neighbouring
cells, recent studies of clinical samples suggested connexins can
contribute to cancer progression through multiple pathways,
namely (1) gap junction intercellular communication, (2) C-
terminal tail-mediated signalling and (3) cell–cell adhesion during
gap junction formation.86 In our data, the expression of GJB2 (and
another receptor for RTN4, RTN4R) was restricted mostly to cancer
cells, whereas the expression of RTN4 was more widely distributed
between cells in the tumour microenvironment including micro-
glial cells, endothelial cells, pericytes and B cells. GJB2 is a tetraspan
membrane protein with two extracellular domains and is
expressed in the plasma membrane. GJB2 has previously been
identified as a gene with prognostic significance in brain,68,69
pancreatic70,71 and breast cancer.72 RTN4 has two long (32 aa)
transmembrane domains and the region between these domains
(NOGO-66) has been shown to mediate protein interaction with
cells expressing RTN4 receptors.87,88 The long transmembrane
domains have been also postulated to confer distinct topological
organisations of this protein, particularly exposing the N-terminus
(the more divergent domain between RTN proteins) extracellularly.
In terms of downstream signalling, RTN4 localises both at the
endoplasmic reticulum and at the plasma membrane. In the
endoplasmic reticulum, it is known to interact with and suppress
the anti-apoptotic functions of Bcl2 and BclXL,89 suggesting a role
as a tumour suppressor. However, more recent data in prostate
cancer has shown that RTN4 regulates cell fate and its over-
expression led to cell cycle arrest and senescence.90 Besides, RTN4
binding to RTN4R, the more established receptor RTN4, con-
tributes to ROCK and STAT3 activation in the cell expressing
RTN4R,88 which can contribute to glioblastoma tumour cells
invasion (through ROCK91) and chronic microglia activation
(through ROCK and STAT392,93). It is still unclear how RNT4’s
interaction with GJB2 and RTN4R contributes to poor prognosis in
glioblastoma, but redistributing RTN4 from the ER to the plasma
membrane and preventing it to interact with other RTN4
intracellular binding partners could be a possible therapeutic
strategy that needs further investigation.
In summary, our analysis of the TCGA GBM database using
segmentation of histopathological images provides new oppor-
tunities for the characterisation of the tumour microenvironment
in glioblastoma within distinctly spatial regions within these very
heterogeneous brain tumours. These results have led to the
identification of novel prognosis-associated region-specific gene
signatures and targets for treating glioblastoma and are now
available to the rest of the brain cancer research community.
ACKNOWLEDGEMENTS
We thank the South Australia Neurological Tumour Bank (SANTB) for providing access
to patient-derived tissue samples and our laboratory colleagues for their continuous
support and fellowship. scRNA-seq experiments were performed at the Australian
Cancer Research Foundation (ACRF) Cancer Genomics and Cancer Discovery
Accelerator facilities, established with the generous support of the Australian Cancer
Research Foundation. We also thanks to Dr. Lisa M. Ebert, Prof. Angel Lopez and Prof.
Stuart M. Pitson at the Centre for Cancer Biology for valuable feedback discussions
during the preparation of this work.
AUTHOR CONTRIBUTIONS
A.Z.S. and G.A.G. conceived the project with input from M.Y., M.S.S. and D.T. The
project was supervised by G.A.G. and M.D.M. A.Z.S., M.D.M. and E.F. analysed the Ivy
GAP data and implemented the DCNN semantic segmentation model. G.A.G. and D.T.
performed bioinformatics analysis. A.Z.S., G.A.G. and M.D.M. analysed the TCGA
samples using the trained DCNN model. K.G.S. has prepared data from Ivy GAP
Dataset for training, validation and test of the DCNN model. N.S.B. inspected all
histological images in the pre-processing phase and results obtained by the models.
R.J.O. and S.P. contributed to bio-specimen collections. A.Z.S. and G.A.G. wrote the
manuscript and illustrated the figures. All authors contributed to manuscript editing.
All authors have read and approved the manuscript.
ADDITIONAL INFORMATION
Ethics approval and consent to participate The study was performed in accordance
with the Declaration of Helsinki and approved by the Southern Adelaide Clinical
Human Research Ethics Committee (#286.10, HREC/17/RAH/358 and HREC/18/SAC/16).
Brain tumour tissue was obtained from the SANTB. Informed consent obtained from
study participants was provided in writing. Consent forms and ethical approval to
enable the collection of brain tumour tissues was provided by the Southern Adelaide
Clinical (SAC) Human Research Ethics Committee (#286.10, HREC/17/RAH/358 and
HREC/18/SAC/16). Brain tumour tissues were obtained from patients undergoing
biopsy or resection of their brain tumour at Flinders Medical Centre in Adelaide, South
Australia, Australia. SANTB specimens were de-identified before use in this study and
all specimens were linked with non-identifiable, comprehensive clinical information.
Consent for publish Images presented in the manuscript correspond to data derived
using de-identified patient-derived samples and there are no details on individuals
reported within the manuscript.
A deep convolutional neural network for segmentation of whole-slide. . .
A Zadeh Shirazi et al.
347
Data availability Computational source codes along with the datasets used for
image segmentation and RNA-seq analysis are provided in the Supplementary
Information and have been deposited at GitHub (https://github.com/amin20/
GBM_WSSM).
Competing interests The authors declare no competing interests.
Funding information This work was supported by grants from the National Health
and Medical Research Council of Australia [grant numbers 1067405, 1123816 to G.A.
G.]; the Cure Brain Cancer Foundation [to G.A.G., R.J.O., and S.P.]; the University of
South Australia and the MAWA Foundation [to G.A.G]; the Neurosurgical Research
Foundation [to R.J.O., S.P. and G.A.G.]; the Cancer Council SA Beat Cancer Project [to
G.A.G.]; and the Australian Research Council [FT160100366 to G.A.G.]. A.Z.S. is
supported by an Australian Government Research Training Program (RTP) Scholar-
ship. The funders had no role in study design, data collection and analysis,
interpretation of data, the decision to publish or preparation of the manuscript.
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41416-021-01394-x.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M. & Simjee, Sh. U. Glioblastoma
multiforme: a review of its epidemiology and pathogenesis through clinical
presentation and treatment. Asian Pac. J. Cancer Prev. 18, 3–9 (2017).
2. Xu, H., Chen, J., Xu, H. & Qin, Z. Geographic variations in the incidence of glio-
blastoma and prognostic factors predictive of overall survival in US adults from
2004–2013. Front. Aging Neurosci. 9, 352 (2017).
3. Tamimi, A. F. & Juweid, M. in Glioblastoma (ed. De Vleeschouwer S), (Exon, 2017).
https://doi.org/10.15586/codon.glioblastoma.2017.ch8.
4. Australian Institute of Health and Welfare. Brain and other central nervous
system cancers. https://www.aihw.gov.au/reports/cancer/brain-other-central-
nervous-system-cancers/contents/table-of-contents (2017).
5. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.
et al. Radiotherapy plus concomitant and adjuvant temozolomide for glio-
blastoma. N. Engl. J. Med. 352, 987–996 (2005).
6. Lieberman, F. Glioblastoma update: molecular biology, diagnosis, treatment,
response assessment, and translational clinical trials. F1000Res. 6, 1892 (2017).
7. Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M. et al.
Glioblastoma heterogeneity and the tumour microenvironment: implications for
preclinical research and development of new treatments. Biochem. Soc. Trans. 47,
625–638 (2019).
8. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D.,
Cavenee, W. K. et al. The 2016 World Health Organization Classification of Tumors
of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820
(2016).
9. Hambardzumyan, D. & Bergers, G. Glioblastoma: Defining tumor niches. Trends
Cancer 1, 252–265 (2015).
10. Olar, A. & Aldape, K. D. Using the molecular classification of glioblastoma to
inform personalized treatment. J. Pathol. 232, 165–177 (2014).
11. Vigneswaran, K., Neill, S. & Hadjipanayis, C. G. Beyond the World Health Orga-
nization grading of infiltrating gliomas: advances in the molecular genetics of
glioma classification. Ann. Transl. Med. 3, 95 (2015).
12. Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R. et al.
Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509–520
(2019).
13. Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S., Samghababi, P.
et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating
front of human glioblastoma. Cell Rep. 21, 1399–1410 (2017).
14. Muller, S., Kohanbash, G., Liu, S. J., Alvarado, B., Carrera, D., Bhaduri, A. et al.
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis
for regional differences in macrophage activation in the tumor microenviron-
ment. Genome Biol. 18, 234 (2017).
15. Muller, S., Liu, S. J., Di Lullo, E., Malatesta, M., Pollen, A. A., Nowakowski, T. J. et al.
Single-cell sequencing maps gene expression to mutational phylogenies in
PDGF- and EGF-driven gliomas. Mol. Syst. Biol. 12, 889 (2016).
16. Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J. et al. An
integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell
178, 835–849 e821 (2019).
17. Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H.
et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glio-
blastoma. Science 344, 1396–1401 (2014).
18. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D. et al.
Integrated genomic analysis identifies clinically relevant subtypes of glio-
blastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer
Cell 17, 98–NF110 (2010).
19. Yuan, J., Levitin, H. M., Frattini, V., Bush, E. C., Boyett, D. M., Samanamud, J. et al.
Single-cell transcriptome analysis of lineage diversity in high-grade glioma.
Genome Med. 10, 57 (2018).
20. Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S.
et al. Stem cell-associated heterogeneity in Glioblastoma results from
intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 10,
1787 (2019).
21. Puchalski, R. B., Shah, N., Miller, J., Dalley, R., Nomura, S. R., Yoon, J.-G. et al. An
anatomic transcriptional atlas of human glioblastoma. Science 360, 660–663
(2018).
22. Bueno, G., Fernandez-Carrobles, M. M., Gonzalez-Lopez, L. & Deniz, O. Glomer-
ulosclerosis identification in whole slide images using semantic segmentation.
Comput. Methods Prog. Biomed. 184, 105273 (2020).
23. Jégou, S., Drozdzal, M., Vazquez, D., Romero, A. & Bengio, Y. The one
hundred layers tiramisu: Fully convolutional densenets for semantic segmenta-
tion. in Proc. IEEE conference on computer vision and pattern recognition workshops
(2017).
24. Mejbri, S., Franchet, C., Reshma, I. A., Mothe, J., Brousset, P. & Faure, E. Deep
Analysis of CNN Settings for New Cancer whole-slide Histological Images Seg-
mentation: the Case of Small Training Sets. in 6th International conference on
BioImaging (BIOIMAGING 2019). (2019).
25. Ronneberger, O., Fischer, P. & Brox, T. U-Net: Convolutional Networks for Biome-
dical Image Segmentation. https://link.springer.com/chapter/10.1007/978-3-319-
24574-4_28 (2015)
26. Cancer Genome Atlas Research, N., Weinstein, J. N., Collisson, E. A., Mills, G. B.,
Shaw, K. R., Ozenberger, B. A. et al. The Cancer Genome Atlas Pan-Cancer analysis
project. Nat. Genet. 45, 1113–1120 (2013).
27. Lovric, M. in Springer reference International encyclopedia of statistical science. 1st
edn. (Springer, International Encyclopedia of Statistical Science, 2011).
28. Menyhárt, O., Weltz, B. & Győrffy, B. MultipleTesting.com: a tool for life science
researchers for multiple hypothesis testing correction. bioRxiv https://doi.org/
10.1101/2021.01.11.426197 (2021).
29. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57,
289–300 (1995).
30. Storey, J. D. The positive false discovery rate: a Bayesian interpretation and the q-
value. Ann. Stat. 31, 2013–2035 (2003).
31. Chollet, F. keras. https://keras.io/. (2015).
32. Girija, S. S. Tensorflow: Large-scale machine learning on heterogeneous distributed
systems. https://www.tensorflow.org/ (2016).
33. Creed, J. H., Gerke, T. A. & Berglund, A. E. MatSurv: Survival analysis and visuali-
zation in MATLAB. J. Open Source Softw. https://doi.org/10.21105/joss.01830
(2020).
34. Patil, A. CellKb Immune: a manually curated database of mammalian immune
marker gene sets optimized for rapid cell type identification. bioRxiv https://doi.
org/10.1101/2020.12.01.389890 (2020).
35. Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn:
a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinfor-
matics 16, 169 (2015).
36. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: a tool for discovery
and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics
10, 48 (2009).
37. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D. et al.
Cytoscape: a software environment for integrated models of biomolecular
interaction networks. Genome Res. 13, 2498–2504 (2003).
38. Ebert, L., Yu, W., Gargett, T., Toubia, J., Kollis, P., Tea, M. et al. Endothelial, pericyte
and tumor cell expression in glioblastoma identifies fibroblast activation protein
(FAP) as an excellent target for immunotherapy. Clin. Transl. Immunol. https://
onlinelibrary.wiley.com/doi/full/10.1002/cti2.1191 (2020).
39. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M. 3rd
et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 e1821
(2019).
40. Cabello-Aguilar, S., Alame, M., Kon-Sun-Tack, F., Fau, C., Lacroix, M. & Colinge, J.
SingleCellSignalR: inference of intercellular networks from single-cell tran-
scriptomics. Nucleic Acids Res. 48, e55 (2020).
41. Karimi, D., Dou, H., Warfield, S. K. & Gholipour, A. Deep learning with noisy labels:
exploring techniques and remedies in medical image analysis. Med. Image Anal.
65, 101759 (2020).
A deep convolutional neural network for segmentation of whole-slide. . .
A Zadeh Shirazi et al.
348
42. Hu, B.-G. & Dong, W.-M. A design of human-like robust AI machines in object
identification. Preprint at arXiv https://arxiv.org/abs/2101.02327 (2021).
43. Couderc, N. GRUBBS: Stata module to perform Grubbs’ test for outliers. https://
ideas.repec.org/c/boc/bocode/s456803.html (2007).
44. de Winter, J. C. F., Gosling, S. D. & Potter, J. Comparing the Pearson and Spearman
correlation coefficients across distributions and sample sizes: a tutorial using
simulations and empirical data. Psychol. Methods 21, 273–290 (2016).
45. Xu, W., Hou, Y., Hung, Y. S. & Zou, Y. A comparative analysis of Spearman’s rho
and Kendall’s tau in normal and contaminated normal models. Signal Process. 93,
261–276 (2013).
46. Shirazi, A. Z., Fornaciari, E., Bagherian, N. S., Ebert, L. M., Koszyca, B. & Gomez, G. A.
DeepSurvNet: deep survival convolutional network for brain cancer survival rate
classification based on histopathological images. Med. Biol. Eng. Comput. 58,
1031–1045 (2020).
47. Zadeh Shirazi, A., Fornaciari, E., McDonnell, M. D., Yaghoobi, M., Cevallos, Y., Tello-
Oquendo, L. et al. The application of deep convolutional neural networks to brain
cancer images: a survey. J. Personalized Med. 10, 224 (2020).
48. Xiao, X., Tang, C., Xiao, S., Fu, C. & Yu, P. Enhancement of proliferation and
invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma
cells. Oncol. Res. 20, 537–544 (2013).
49. Tanaka, S., Batchelor, T. T., Iafrate, A. J., Dias-Santagata, D., Borger, D. R., Ellisen, L.
W. et al. PIK3CA activating mutations are associated with more disseminated
disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol.
Commun. 7, 66 (2019).
50. Weber, G. L., Parat, M. O., Binder, Z. A., Gallia, G. L. & Riggins, G. J. Abrogation of
PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma
multiforme cells. Oncotarget 2, 833–849 (2011).
51. Zhang, L. H., Yin, Y. H., Chen, H. Z., Feng, S. Y., Liu, J. L., Chen, L. et al. TRIM24
promotes stemness and invasiveness of glioblastoma cells via activating SOX2
expression. Neuro Oncol https://doi.org/10.1093/neuonc/noaa138 (2020).
52. Mair, D. B., Ames, H. M. & Li, R. Mechanisms of invasion and motility of high-grade
gliomas in the brain. Mol. Biol. Cell 29, 2509–2515 (2018).
53. Juliano, J., Gil, O., Hawkins-Daarud, A., Noticewala, S., Rockne, R. C., Gallaher, J.
et al. Comparative dynamics of microglial and glioma cell motility at the infil-
trative margin of brain tumours. J. R. Soc. Interface https://doi.org/10.1098/
rsif.2017.0582 (2018).
54. Pacioni, S., D’Alessandris, Q. G., Buccarelli, M., Boe, A., Martini, M., Larocca, L. M.
et al. Brain invasion along perivascular spaces by glioma cells: relationship with
blood-brain barrier. Cancers https://doi.org/10.3390/cancers12010018 (2019).
55. Brahm, C. G., van Linde, M. E., Enting, R. H., Schuur, M., Otten, R. H. J., Heymans, M.
W. et al. The Current status of immune checkpoint inhibitors in neuro-oncology: a
systematic review. Cancers (Basel) https://doi.org/10.3390/cancers12030586
(2020).
56. Xiao, Z. A., Xie, D. H., Hu, P., Xia, K., Cai, F. & Pan, Q. [Functional interaction of the
C-terminal of Nogo protein with connexin 26 and the expression of Nogo’s mRNA
in the murine inner ear]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23, 492–496
(2006).
57. Di Lorenzo, A., Manes, T. D., Davalos, A., Wright, P. L. & Sessa, W. C. Endothelial
reticulon-4B (Nogo-B) regulates ICAM-1-mediated leukocyte transmigration and
acute inflammation. Blood 117, 2284–2295 (2011).
58. Jin, S. G., Ryu, H. H., Li, S. Y., Li, C. H., Lim, S. H., Jang, W. Y. et al. Nogo-A inhibits the
migration and invasion of human malignant glioma U87MG cells. Oncol. Rep. 35,
3395–3402 (2016).
59. Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes,
consequences, challenges and opportunities. Cell Mol. Life Sci. 77, 1745–1770
(2020).
60. Walchli, T., Pernet, V., Weinmann, O., Shiu, J. Y., Guzik-Kornacka, A., Decrey, G.
et al. Nogo-A is a negative regulator of CNS angiogenesis. Proc. Natl Acad. Sci. USA
110, E1943–E1952 (2013).
61. Walchli, T., Ulmann-Schuler, A., Hintermuller, C., Meyer, E., Stampanoni, M., Car-
meliet, P. et al. Nogo-A regulates vascular network architecture in the postnatal
brain. J. Cereb. Blood Flow. Metab. 37, 614–631 (2017).
62. Oshima, A., Tani, K., Hiroaki, Y., Fujiyoshi, Y. & Sosinsky, G. E. Three-dimensional
structure of a human connexin26 gap junction channel reveals a plug in the
vestibule. Proc. Natl Acad. Sci. USA 104, 10034–10039 (2007).
63. Bennett, B. C., Purdy, M. D., Baker, K. A., Acharya, C., McIntire, W. E., Stevens, R. C.
et al. An electrostatic mechanism for Ca(2+)-mediated regulation of gap junction
channels. Nat. Commun. 7, 8770 (2016).
64. Bicego, M., Beltramello, M., Melchionda, S., Carella, M., Piazza, V., Zelante, L. et al.
Pathogenetic role of the deafness-related M34T mutation of Cx26. Hum. Mol.
Genet. 15, 2569–Cx2587 (2006).
65. Choi, S. Y., Park, H. J., Lee, K. Y., Dinh, E. H., Chang, Q., Ahmad, S. et al. Different
functional consequences of two missense mutations in the GJB2 gene associated
with non-syndromic hearing loss. Hum. Mutat. 30, E716–E727 (2009).
66. Maeda, S., Nakagawa, S., Suga, M., Yamashita, E., Oshima, A., Fujiyoshi, Y. et al.
Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature
458, 597–602 (2009).
67. Oshima, A., Tani, K., Toloue, M. M., Hiroaki, Y., Smock, A., Inukai, S. et al. Asym-
metric configurations and N-terminal rearrangements in connexin26 gap junc-
tion channels. J. Mol. Biol. 405, 724–735 (2011).
68. Berezovsky, A. D., Poisson, L. M., Cherba, D., Webb, C. P., Transou, A. D., Lemke, N.
W. et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and
astrocytic differentiation. Neoplasia 16, 193–206 (2014). 206 e119-125.
69. Yu, S. C., Xiao, H. L., Jiang, X. F., Wang, Q. L., Li, Y., Yang, X. J. et al. Connexin 43
reverses malignant phenotypes of glioma stem cells by modulating E-cadherin.
Stem Cells 30, 108–120 (2012).
70. Sun, D., Jin, H., Zhang, J. & Tan, X. Integrated whole genome microarray analysis
and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as pre-
dictive biomarkers for pancreatic cancer. Cancer Cell Int. 18, 174 (2018).
71. Zhu, T., Gao, Y. F., Chen, Y. X., Wang, Z. B., Yin, J. Y., Mao, X. Y. et al. Genome-scale
analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pan-
creatic cancer. Oncotarget 8, 21281–21289 (2017).
72. Shettar, A., Damineni, S., Mukherjee, G. & Kondaiah, P. Gap junction beta2
expression is negatively associated with the estrogen receptor status in breast
cancer tissues and is a regulator of breast tumorigenesis. Oncol. Rep. 40,
3645–3653 (2018).
73. Berens, M. E., Sood, A., Barnholtz-Sloan, J. S., Graf, J. F., Cho, S., Kim, S. et al.
Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-
type diffuse gliomas. PLoS ONE 14, e0219724 (2019).
74. Bernstock, J. D., Vicario, N., Rong, L., Valdes, P. A., Choi, B. D., Chen, J. A. et al. A
novel in situ multiplex immunofluorescence panel for the assessment of tumor
immunopathology and response to virotherapy in pediatric glioblastoma reveals
a role for checkpoint protein inhibition. Oncoimmunology 8, e1678921 (2019).
75. Cieremans, D., Kim, J. Y., Valencia, A., Santos, J., Bordeaux, J., Tran, T. et al. Pre-
dictive evaluation of quantitative spatial profiling of the tumor microenviron-
ment by multiplex immunofluorescence in recurrent glioblastoma treated with
PD-1 inhibitors. J. Clin. Oncol. 38, e14524–e14524 (2020).
76. Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O’Byrne, K., Rezaei, N.
et al. Understanding the tumor microenvironment for effective immunotherapy.
Med. Res. Rev. https://doi.org/10.1002/med.21765 (2020).
77. Couturier, C. P., Ayyadhury, S., Le, P. U., Nadaf, J., Monlong, J., Riva, G. et al. Single-
cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelop-
mental hierarchy. Nat. Commun. 11, 3406 (2020).
78. Jia, D., Li, S., Li, D., Xue, H., Yang, D. & Liu, Y. Mining TCGA database for genes of
prognostic value in glioblastoma microenvironment. Aging (Albany NY) 10,
592–605 (2018).
79. Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., Van
Ginderachter, J. A. Understanding the glioblastoma immune microenvironment
as basis for the development of new immunotherapeutic strategies. elife https://
doi.org/10.7554/eLife.52176 (2020).
80. Rajapakse, V. N., Herrada, S. & Lavi, O. Phenotype stability under dynamic brain-
tumor environment stimuli maps glioblastoma progression in patients. Sci. Adv. 6,
eaaz4125 (2020).
81. Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kückelhaus, J. et al. Lineage
and spatial mapping of glioblastoma-associated immunity. bioRxiv https://doi.
org/10.1101/2020.06.01.121467 (2020).
82. Wang, Y., Mashock, M., Tong, Z., Mu, X., Chen, H., Zhou, X. et al. Changing
technologies of RNA sequencing and their applications in clinical oncology. Front.
Oncol. 10, 447 (2020).
83. Crosetto, N., Bienko, M. & van Oudenaarden, A. Spatially resolved transcriptomics
and beyond. Nat. Rev. Genet. 16, 57–66 (2015).
84. Zanotelli, V. R., Leutenegger, M., Lun, X. K., Georgi, F., de Souza, N. & Bodenmiller,
B. A quantitative analysis of the interplay of environment, neighborhood, and cell
state in 3D spheroids. Mol. Syst. Biol. 16, e9798 (2020).
85. Krieger, T. G., Tirier, S. M., Park, J., Jechow, K., Eisemann, T., Peterziel, H. et al.
Modeling glioblastoma invasion using human brain organoids and single-cell
transcriptomics. Neuro Oncol. 22, 1138–1149 (2020).
86. Wu, J. I. & Wang, L. H. Emerging roles of gap junction proteins connexins in
cancer metastasis, chemoresistance and clinical application. J. Biomed. Sci. 26, 8
(2019).
87. Yang, Y. S. & Strittmatter, S. M. The reticulons: a family of proteins with diverse
functions. Genome Biol. 8, 234 (2007).
88. Pradhan, L. K. & Das, S. K. The regulatory role of reticulons in neurodegeneration:
insights underpinning therapeutic potential for neurodegenerative diseases. Cell
Mol. Neurobiol. https://doi.org/10.1007/s10571-020-00893-4 (2020).
89. Tagami, S., Eguchi, Y., Kinoshita, M., Takeda, M. & Tsujimoto, Y. A novel protein,
RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and
reduces their anti-apoptotic activity. Oncogene 19, 5736–5746 (2000).
A deep convolutional neural network for segmentation of whole-slide. . .
A Zadeh Shirazi et al.
349
90. Zhao, H., Su, W., Zhu, C., Zeng, T., Yang, S., Wu, W. et al. Cell fate regulation
by reticulon-4 in human prostate cancers. J. Cell Physiol. 234, 10372–10385
(2019).
91. Barnes, J. M., Kaushik, S., Bainer, R. O., Sa, J. K., Woods, E. C., Kai, F. et al. A tension-
mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glio-
blastoma. Nat. Cell Biol. 20, 1203–1214 (2018).
92. Yan, J., Zhou, X., Guo, J. J., Mao, L., Wang, Y. J., Sun, J. et al. Nogo-66 inhibits
adhesion and migration of microglia via GTPase Rho pathway in vitro. J. Neu-
rochem. 120, 721–731 (2012).
93. Fang, Y., Yan, J., Li, C., Zhou, X., Yao, L., Pang, T. et al. The Nogo/Nogo
receptor (NgR) signal is involved in neuroinflammation through the
regulation of microglial inflammatory activation. J. Biol. Chem. 290, 28901–28914
(2015).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
A deep convolutional neural network for segmentation of whole-slide. . .
A Zadeh Shirazi et al.
350
